Payment overview · 2025
General Payments
$225.47
10 reported records · 7 companies
Healthcare provider profile · identity verified
May Kim, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FLOWER MOUND, TX · NPI 1386844744
Verified facts
What the public records show
CMS Open Payments records show May Kim, M.D. received $225.47 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.05 | 32.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.39 | 13.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $30.51 | 13.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.26 | 11.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.03 | 10.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.39 | 9.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.84 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $225.47 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $57.83 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $30.51 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 159 |
| Metformin Hcl | Metformin Hcl | 198 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 139 | 57 |
| Losartan Potassium | Losartan Potassium | 134 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 48 |
| Prednisone | Prednisone | 109 | 79 |
| Alendronate Sodium | Alendronate Sodium | 101 | 41 |
| Azithromycin | Azithromycin | 97 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 56 |
| Metformin Hcl Er | Metformin Hcl | 73 | 27 |
| Lisinopril | Lisinopril | 72 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 34 |
| Ozempic | Semaglutide | 56 | 17 |
| Progesterone | Progesterone, Micronized | 52 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 21 |
| Ezetimibe | Ezetimibe | 49 | 23 |
| Simvastatin | Simvastatin | 49 | 18 |
| Meloxicam | Meloxicam | 46 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 15 |
| Tramadol Hcl | Tramadol Hcl | 41 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 23 |
| Amoxicillin | Amoxicillin | 35 | 32 |
| Temazepam | Temazepam | 35 | 18 |
| Glipizide Er | Glipizide | 34 | 14 |
| Finasteride | Finasteride | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 32 | 13 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 28 |
| Naproxen | Naproxen | 27 | 22 |
| Cephalexin | Cephalexin | 26 | 21 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 18 |
| Cefdinir | Cefdinir | 25 | 20 |
| Gabapentin | Gabapentin | 25 | 17 |
| Sertraline Hcl | Sertraline Hcl | 25 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 20 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Omeprazole | Omeprazole | 17 | 11 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 12 |
| Methylprednisolone | Methylprednisolone | 16 | 12 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Prolia | Denosumab | 15 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $225.47 · 10 records | Amgen Inc. | APTIMA, Cologuard Collection Kit, EVENITY, JARDIANCE, REPATHA, VYEPTI, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error